Tonix Pharmaceuticals (TNXP) announced the appointment of James “Jim” Hunter to its Board of Directors, effective June 12, 2025. Hunter most recently served as Executive Vice President, Commercial at Tonix, where he was responsible for building the Company’s commercial subsidiary, Tonix Medicines, and successfully executing its entry into the migraine market.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNXP:
- Tonix Pharmaceuticals files $500M mixed securities shelf
- Tonix Pharma Signs Major Sales Agreements for Funding
- Tonix Pharmaceuticals price target raised to $65 from $11 at Alliance Global Partners
- Tonix Pharma Begins Phase 2 OASIS Trial
- Tonix Pharmaceuticals announces first patient dosed in Phase 2 OASIS study